nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—HTR2C—metabolic syndrome X	0.754	1	CbGaD
Duloxetine—White blood cell count increased—Metformin—metabolic syndrome X	0.0111	0.0821	CcSEcCtD
Duloxetine—Seasonal allergy—Metformin—metabolic syndrome X	0.0106	0.0786	CcSEcCtD
Duloxetine—Rhinitis seasonal—Metformin—metabolic syndrome X	0.0102	0.0755	CcSEcCtD
Duloxetine—SLC6A2—sympathetic nervous system—metabolic syndrome X	0.00991	0.193	CbGeAlD
Duloxetine—HTR2A—arteriole—metabolic syndrome X	0.00935	0.182	CbGeAlD
Duloxetine—Viral diarrhoea—Metformin—metabolic syndrome X	0.00851	0.0631	CcSEcCtD
Duloxetine—SLC6A2—autonomic nervous system—metabolic syndrome X	0.00666	0.129	CbGeAlD
Duloxetine—HTR2A—sympathetic nervous system—metabolic syndrome X	0.00596	0.116	CbGeAlD
Duloxetine—Epigastric discomfort—Metformin—metabolic syndrome X	0.00422	0.0313	CcSEcCtD
Duloxetine—Loose stools—Metformin—metabolic syndrome X	0.00401	0.0298	CcSEcCtD
Duloxetine—HTR2A—autonomic nervous system—metabolic syndrome X	0.004	0.0778	CbGeAlD
Duloxetine—NPY1R—adipose tissue—metabolic syndrome X	0.00341	0.0663	CbGeAlD
Duloxetine—Upset stomach—Metformin—metabolic syndrome X	0.00339	0.0251	CcSEcCtD
Duloxetine—Rigors—Metformin—metabolic syndrome X	0.00272	0.0202	CcSEcCtD
Duloxetine—Blood disorder—Metformin—metabolic syndrome X	0.00266	0.0197	CcSEcCtD
Duloxetine—Contusion—Metformin—metabolic syndrome X	0.00255	0.0189	CcSEcCtD
Duloxetine—NPY1R—liver—metabolic syndrome X	0.00239	0.0465	CbGeAlD
Duloxetine—HTR2A—artery—metabolic syndrome X	0.00227	0.0441	CbGeAlD
Duloxetine—HTR2A—endothelium—metabolic syndrome X	0.00192	0.0373	CbGeAlD
Duloxetine—Ear pain—Metformin—metabolic syndrome X	0.00189	0.014	CcSEcCtD
Duloxetine—HTR2A—blood vessel—metabolic syndrome X	0.00177	0.0344	CbGeAlD
Duloxetine—Renal impairment—Metformin—metabolic syndrome X	0.00169	0.0126	CcSEcCtD
Duloxetine—Hypoglycaemia—Metformin—metabolic syndrome X	0.00165	0.0123	CcSEcCtD
Duloxetine—Lethargy—Metformin—metabolic syndrome X	0.00165	0.0122	CcSEcCtD
Duloxetine—Pain in extremity—Metformin—metabolic syndrome X	0.00161	0.012	CcSEcCtD
Duloxetine—Migraine—Metformin—metabolic syndrome X	0.00159	0.0118	CcSEcCtD
Duloxetine—Dehydration—Metformin—metabolic syndrome X	0.0015	0.0111	CcSEcCtD
Duloxetine—Liver function test abnormal—Metformin—metabolic syndrome X	0.00149	0.011	CcSEcCtD
Duloxetine—Abdominal pain upper—Metformin—metabolic syndrome X	0.00147	0.0109	CcSEcCtD
Duloxetine—Breast disorder—Metformin—metabolic syndrome X	0.00146	0.0108	CcSEcCtD
Duloxetine—Cramp muscle—Metformin—metabolic syndrome X	0.00145	0.0108	CcSEcCtD
Duloxetine—Nasopharyngitis—Metformin—metabolic syndrome X	0.00144	0.0107	CcSEcCtD
Duloxetine—Influenza—Metformin—metabolic syndrome X	0.00139	0.0103	CcSEcCtD
Duloxetine—Pancreatitis—Metformin—metabolic syndrome X	0.00137	0.0101	CcSEcCtD
Duloxetine—Sweating increased—Metformin—metabolic syndrome X	0.00136	0.0101	CcSEcCtD
Duloxetine—Abdominal discomfort—Metformin—metabolic syndrome X	0.00134	0.00991	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Metformin—metabolic syndrome X	0.0013	0.00961	CcSEcCtD
Duloxetine—Infestation NOS—Metformin—metabolic syndrome X	0.00124	0.00922	CcSEcCtD
Duloxetine—Infestation—Metformin—metabolic syndrome X	0.00124	0.00922	CcSEcCtD
Duloxetine—Hepatobiliary disease—Metformin—metabolic syndrome X	0.00118	0.00872	CcSEcCtD
Duloxetine—Hepatitis—Metformin—metabolic syndrome X	0.00112	0.00827	CcSEcCtD
Duloxetine—Hypoaesthesia—Metformin—metabolic syndrome X	0.00111	0.00823	CcSEcCtD
Duloxetine—Oedema peripheral—Metformin—metabolic syndrome X	0.0011	0.00815	CcSEcCtD
Duloxetine—Connective tissue disorder—Metformin—metabolic syndrome X	0.0011	0.00813	CcSEcCtD
Duloxetine—Eye disorder—Metformin—metabolic syndrome X	0.00104	0.00773	CcSEcCtD
Duloxetine—Flushing—Metformin—metabolic syndrome X	0.00104	0.00768	CcSEcCtD
Duloxetine—Cardiac disorder—Metformin—metabolic syndrome X	0.00104	0.00768	CcSEcCtD
Duloxetine—Angiopathy—Metformin—metabolic syndrome X	0.00101	0.00751	CcSEcCtD
Duloxetine—Immune system disorder—Metformin—metabolic syndrome X	0.00101	0.00747	CcSEcCtD
Duloxetine—Mediastinal disorder—Metformin—metabolic syndrome X	0.00101	0.00746	CcSEcCtD
Duloxetine—Chills—Metformin—metabolic syndrome X	0.001	0.00742	CcSEcCtD
Duloxetine—Erythema—Metformin—metabolic syndrome X	0.000971	0.0072	CcSEcCtD
Duloxetine—Malnutrition—Metformin—metabolic syndrome X	0.000971	0.0072	CcSEcCtD
Duloxetine—Flatulence—Metformin—metabolic syndrome X	0.000957	0.0071	CcSEcCtD
Duloxetine—Dysgeusia—Metformin—metabolic syndrome X	0.000951	0.00705	CcSEcCtD
Duloxetine—Muscle spasms—Metformin—metabolic syndrome X	0.000934	0.00693	CcSEcCtD
Duloxetine—Vision blurred—Metformin—metabolic syndrome X	0.000915	0.00679	CcSEcCtD
Duloxetine—Fluoxetine—HTR2C—metabolic syndrome X	0.000911	0.481	CrCbGaD
Duloxetine—Tremor—Metformin—metabolic syndrome X	0.00091	0.00675	CcSEcCtD
Duloxetine—Ill-defined disorder—Metformin—metabolic syndrome X	0.000901	0.00668	CcSEcCtD
Duloxetine—Malaise—Metformin—metabolic syndrome X	0.000876	0.0065	CcSEcCtD
Duloxetine—Syncope—Metformin—metabolic syndrome X	0.000871	0.00646	CcSEcCtD
Duloxetine—Palpitations—Metformin—metabolic syndrome X	0.000858	0.00637	CcSEcCtD
Duloxetine—Loss of consciousness—Metformin—metabolic syndrome X	0.000853	0.00633	CcSEcCtD
Duloxetine—Hypertension—Metformin—metabolic syndrome X	0.000838	0.00622	CcSEcCtD
Duloxetine—Chest pain—Metformin—metabolic syndrome X	0.000827	0.00613	CcSEcCtD
Duloxetine—Myalgia—Metformin—metabolic syndrome X	0.000827	0.00613	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Metformin—metabolic syndrome X	0.000821	0.00609	CcSEcCtD
Duloxetine—Discomfort—Metformin—metabolic syndrome X	0.000817	0.00606	CcSEcCtD
Duloxetine—Oedema—Metformin—metabolic syndrome X	0.000792	0.00588	CcSEcCtD
Duloxetine—HTR2A—cardiovascular system—metabolic syndrome X	0.000789	0.0153	CbGeAlD
Duloxetine—Infection—Metformin—metabolic syndrome X	0.000787	0.00584	CcSEcCtD
Duloxetine—Shock—Metformin—metabolic syndrome X	0.00078	0.00578	CcSEcCtD
Duloxetine—Nervous system disorder—Metformin—metabolic syndrome X	0.000777	0.00577	CcSEcCtD
Duloxetine—Thrombocytopenia—Metformin—metabolic syndrome X	0.000776	0.00576	CcSEcCtD
Duloxetine—HTR2A—kidney—metabolic syndrome X	0.000772	0.015	CbGeAlD
Duloxetine—Skin disorder—Metformin—metabolic syndrome X	0.00077	0.00571	CcSEcCtD
Duloxetine—Hyperhidrosis—Metformin—metabolic syndrome X	0.000766	0.00568	CcSEcCtD
Duloxetine—Anorexia—Metformin—metabolic syndrome X	0.000755	0.0056	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Metformin—metabolic syndrome X	0.000722	0.00536	CcSEcCtD
Duloxetine—Paraesthesia—Metformin—metabolic syndrome X	0.000712	0.00528	CcSEcCtD
Duloxetine—Somnolence—Metformin—metabolic syndrome X	0.000704	0.00523	CcSEcCtD
Duloxetine—CYP2D6—kidney—metabolic syndrome X	0.000703	0.0137	CbGeAlD
Duloxetine—Dyspepsia—Metformin—metabolic syndrome X	0.000698	0.00517	CcSEcCtD
Duloxetine—Decreased appetite—Metformin—metabolic syndrome X	0.000689	0.00511	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Metformin—metabolic syndrome X	0.000684	0.00508	CcSEcCtD
Duloxetine—Fatigue—Metformin—metabolic syndrome X	0.000683	0.00507	CcSEcCtD
Duloxetine—Constipation—Metformin—metabolic syndrome X	0.000678	0.00503	CcSEcCtD
Duloxetine—Feeling abnormal—Metformin—metabolic syndrome X	0.000653	0.00484	CcSEcCtD
Duloxetine—Gastrointestinal pain—Metformin—metabolic syndrome X	0.000648	0.00481	CcSEcCtD
Duloxetine—Urticaria—Metformin—metabolic syndrome X	0.00063	0.00467	CcSEcCtD
Duloxetine—Abdominal pain—Metformin—metabolic syndrome X	0.000626	0.00465	CcSEcCtD
Duloxetine—CYP1A2—liver—metabolic syndrome X	0.000624	0.0121	CbGeAlD
Duloxetine—Atomoxetine—HTR2C—metabolic syndrome X	0.000585	0.309	CrCbGaD
Duloxetine—Asthenia—Metformin—metabolic syndrome X	0.000569	0.00422	CcSEcCtD
Duloxetine—Pruritus—Metformin—metabolic syndrome X	0.000561	0.00416	CcSEcCtD
Duloxetine—Diarrhoea—Metformin—metabolic syndrome X	0.000542	0.00402	CcSEcCtD
Duloxetine—Dizziness—Metformin—metabolic syndrome X	0.000524	0.00389	CcSEcCtD
Duloxetine—Vomiting—Metformin—metabolic syndrome X	0.000504	0.00374	CcSEcCtD
Duloxetine—Rash—Metformin—metabolic syndrome X	0.0005	0.00371	CcSEcCtD
Duloxetine—Dermatitis—Metformin—metabolic syndrome X	0.000499	0.0037	CcSEcCtD
Duloxetine—Headache—Metformin—metabolic syndrome X	0.000496	0.00368	CcSEcCtD
Duloxetine—HTR2A—liver—metabolic syndrome X	0.000488	0.00948	CbGeAlD
Duloxetine—Nausea—Metformin—metabolic syndrome X	0.000471	0.00349	CcSEcCtD
Duloxetine—CYP2D6—liver—metabolic syndrome X	0.000444	0.00864	CbGeAlD
Duloxetine—Fluoxetine—ALB—metabolic syndrome X	0.000397	0.21	CrCbGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—HSD11B1—metabolic syndrome X	4.86e-05	0.00084	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—AGT—metabolic syndrome X	4.83e-05	0.000835	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—PPARA—metabolic syndrome X	4.79e-05	0.000828	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—IL6—metabolic syndrome X	4.77e-05	0.000824	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MTNR1B—metabolic syndrome X	4.74e-05	0.00082	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IRS1—metabolic syndrome X	4.71e-05	0.000814	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL2—metabolic syndrome X	4.53e-05	0.000784	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—INS—metabolic syndrome X	4.51e-05	0.00078	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—APOA1—metabolic syndrome X	4.49e-05	0.000776	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—GHRL—metabolic syndrome X	4.44e-05	0.000768	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCL2—metabolic syndrome X	4.44e-05	0.000767	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CCL5—metabolic syndrome X	4.43e-05	0.000766	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MTNR1B—metabolic syndrome X	4.38e-05	0.000758	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IGF1—metabolic syndrome X	4.36e-05	0.000754	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TNF—metabolic syndrome X	4.36e-05	0.000753	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TRIB3—metabolic syndrome X	4.27e-05	0.000738	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RBP4—metabolic syndrome X	4.27e-05	0.000738	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—PPARA—metabolic syndrome X	4.24e-05	0.000733	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—HDAC3—metabolic syndrome X	4.23e-05	0.000731	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CNR1—metabolic syndrome X	4.21e-05	0.000727	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—AGT—metabolic syndrome X	4.19e-05	0.000725	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SERPINE1—metabolic syndrome X	4.14e-05	0.000716	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—LPA—metabolic syndrome X	4.13e-05	0.000714	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—HTR2C—metabolic syndrome X	4.07e-05	0.000704	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—GHRL—metabolic syndrome X	4.04e-05	0.000698	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCL5—metabolic syndrome X	4.02e-05	0.000695	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PLA2G4A—metabolic syndrome X	4.01e-05	0.000693	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G6—metabolic syndrome X	4e-05	0.000692	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—APOA1—metabolic syndrome X	3.98e-05	0.000688	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CCL2—metabolic syndrome X	3.98e-05	0.000687	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOA5—metabolic syndrome X	3.96e-05	0.000685	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NOS3—metabolic syndrome X	3.95e-05	0.000684	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—GHRL—metabolic syndrome X	3.86e-05	0.000667	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CNR1—metabolic syndrome X	3.82e-05	0.000661	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOC3—metabolic syndrome X	3.78e-05	0.000654	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—FMO3—metabolic syndrome X	3.78e-05	0.000654	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AGT—metabolic syndrome X	3.7e-05	0.00064	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HTR2C—metabolic syndrome X	3.7e-05	0.000639	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—TRIB3—metabolic syndrome X	3.68e-05	0.000637	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CNR1—metabolic syndrome X	3.65e-05	0.000632	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HDAC3—metabolic syndrome X	3.61e-05	0.000624	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ALB—metabolic syndrome X	3.56e-05	0.000615	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL6—metabolic syndrome X	3.51e-05	0.000608	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—GHRL—metabolic syndrome X	3.5e-05	0.000606	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CCL2—metabolic syndrome X	3.45e-05	0.000597	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HTR2C—metabolic syndrome X	3.41e-05	0.00059	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—AKT1—metabolic syndrome X	3.39e-05	0.000586	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MLXIPL—metabolic syndrome X	3.37e-05	0.000583	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—EPHX2—metabolic syndrome X	3.37e-05	0.000583	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AGT—metabolic syndrome X	3.36e-05	0.000582	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL6—metabolic syndrome X	3.34e-05	0.000577	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CNR1—metabolic syndrome X	3.32e-05	0.000574	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CYBA—metabolic syndrome X	3.31e-05	0.000572	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—metabolic syndrome X	3.28e-05	0.000568	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOC3—metabolic syndrome X	3.26e-05	0.000564	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCL5—metabolic syndrome X	3.26e-05	0.000564	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GHRL—metabolic syndrome X	3.24e-05	0.00056	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MTNR1B—metabolic syndrome X	3.23e-05	0.000558	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—FMO3—metabolic syndrome X	3.2e-05	0.000554	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—G6PC2—metabolic syndrome X	3.17e-05	0.000548	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CETP—metabolic syndrome X	3.17e-05	0.000548	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ALB—metabolic syndrome X	3.15e-05	0.000545	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TRIB3—metabolic syndrome X	3.15e-05	0.000544	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RBP4—metabolic syndrome X	3.15e-05	0.000544	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HDAC3—metabolic syndrome X	3.14e-05	0.000542	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—metabolic syndrome X	3.13e-05	0.000541	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—AKT1—metabolic syndrome X	3.08e-05	0.000532	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CNR1—metabolic syndrome X	3.07e-05	0.00053	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—metabolic syndrome X	3.03e-05	0.000524	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL5—metabolic syndrome X	2.96e-05	0.000512	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PLA2G4A—metabolic syndrome X	2.95e-05	0.00051	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—SREBF1—metabolic syndrome X	2.94e-05	0.000509	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—HMGCR—metabolic syndrome X	2.86e-05	0.000495	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MLXIPL—metabolic syndrome X	2.86e-05	0.000494	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—EPHX2—metabolic syndrome X	2.86e-05	0.000494	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCL5—metabolic syndrome X	2.83e-05	0.00049	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MTNR1B—metabolic syndrome X	2.8e-05	0.000485	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOC3—metabolic syndrome X	2.79e-05	0.000482	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCL2—metabolic syndrome X	2.77e-05	0.000479	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TRIB3—metabolic syndrome X	2.73e-05	0.000472	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RBP4—metabolic syndrome X	2.73e-05	0.000472	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AGT—metabolic syndrome X	2.73e-05	0.000472	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—metabolic syndrome X	2.72e-05	0.00047	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—FABP4—metabolic syndrome X	2.7e-05	0.000466	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—G6PC2—metabolic syndrome X	2.69e-05	0.000464	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TGFB1—metabolic syndrome X	2.62e-05	0.000452	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL5—metabolic syndrome X	2.57e-05	0.000445	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PLA2G4A—metabolic syndrome X	2.56e-05	0.000443	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HSD11B1—metabolic syndrome X	2.56e-05	0.000442	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—metabolic syndrome X	2.55e-05	0.000441	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF2—metabolic syndrome X	2.51e-05	0.000433	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AGT—metabolic syndrome X	2.48e-05	0.000428	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—metabolic syndrome X	2.47e-05	0.000427	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CYBA—metabolic syndrome X	2.44e-05	0.000421	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOB—metabolic syndrome X	2.43e-05	0.000421	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOC3—metabolic syndrome X	2.42e-05	0.000418	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GHRL—metabolic syndrome X	2.38e-05	0.000412	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL5—metabolic syndrome X	2.38e-05	0.000411	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AGT—metabolic syndrome X	2.37e-05	0.00041	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PLA2G4A—metabolic syndrome X	2.37e-05	0.000409	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LPL—metabolic syndrome X	2.32e-05	0.000402	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—FABP4—metabolic syndrome X	2.28e-05	0.000395	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—G6PD—metabolic syndrome X	2.28e-05	0.000394	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CNR1—metabolic syndrome X	2.26e-05	0.00039	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HDAC3—metabolic syndrome X	2.22e-05	0.000384	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HTR2C—metabolic syndrome X	2.18e-05	0.000377	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LPA—metabolic syndrome X	2.17e-05	0.000376	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GCKR—metabolic syndrome X	2.17e-05	0.000376	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HSD11B1—metabolic syndrome X	2.16e-05	0.000374	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AGT—metabolic syndrome X	2.15e-05	0.000372	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CYBA—metabolic syndrome X	2.11e-05	0.000366	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PLA2G6—metabolic syndrome X	2.1e-05	0.000364	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOB—metabolic syndrome X	2.1e-05	0.000363	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOA5—metabolic syndrome X	2.08e-05	0.00036	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GHRL—metabolic syndrome X	2.07e-05	0.000358	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—metabolic syndrome X	2.04e-05	0.000353	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL2—metabolic syndrome X	2.04e-05	0.000353	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—LPL—metabolic syndrome X	2e-05	0.000346	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AGT—metabolic syndrome X	1.99e-05	0.000344	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—metabolic syndrome X	1.97e-05	0.000341	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CNR1—metabolic syndrome X	1.96e-05	0.000339	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOE—metabolic syndrome X	1.95e-05	0.000337	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LEP—metabolic syndrome X	1.95e-05	0.000337	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TRIB3—metabolic syndrome X	1.94e-05	0.000335	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—G6PD—metabolic syndrome X	1.93e-05	0.000334	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOA1—metabolic syndrome X	1.92e-05	0.000333	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CD36—metabolic syndrome X	1.9e-05	0.000329	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HDAC3—metabolic syndrome X	1.88e-05	0.000326	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF2—metabolic syndrome X	1.85e-05	0.000319	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GCKR—metabolic syndrome X	1.84e-05	0.000318	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LPA—metabolic syndrome X	1.84e-05	0.000318	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AKT1—metabolic syndrome X	1.82e-05	0.000314	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOB—metabolic syndrome X	1.79e-05	0.00031	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLA2G6—metabolic syndrome X	1.78e-05	0.000308	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL2—metabolic syndrome X	1.77e-05	0.000306	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—metabolic syndrome X	1.77e-05	0.000306	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOA5—metabolic syndrome X	1.76e-05	0.000305	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL5—metabolic syndrome X	1.75e-05	0.000302	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PLA2G4A—metabolic syndrome X	1.74e-05	0.000301	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IRS1—metabolic syndrome X	1.74e-05	0.0003	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NAMPT—metabolic syndrome X	1.74e-05	0.0003	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LIPC—metabolic syndrome X	1.73e-05	0.000298	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GCK—metabolic syndrome X	1.73e-05	0.000298	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOC3—metabolic syndrome X	1.72e-05	0.000297	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—metabolic syndrome X	1.71e-05	0.000296	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LPL—metabolic syndrome X	1.71e-05	0.000296	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—metabolic syndrome X	1.68e-05	0.00029	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CETP—metabolic syndrome X	1.67e-05	0.000288	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—INS—metabolic syndrome X	1.66e-05	0.000288	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—metabolic syndrome X	1.66e-05	0.000287	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TRIB3—metabolic syndrome X	1.64e-05	0.000284	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL2—metabolic syndrome X	1.64e-05	0.000283	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1—metabolic syndrome X	1.61e-05	0.000278	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF2—metabolic syndrome X	1.6e-05	0.000277	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SCARB1—metabolic syndrome X	1.59e-05	0.000276	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOB—metabolic syndrome X	1.56e-05	0.000269	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SREBF1—metabolic syndrome X	1.55e-05	0.000268	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SERPINE1—metabolic syndrome X	1.53e-05	0.000264	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL5—metabolic syndrome X	1.52e-05	0.000263	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PLA2G4A—metabolic syndrome X	1.51e-05	0.000262	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMGCR—metabolic syndrome X	1.51e-05	0.00026	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GOT2—metabolic syndrome X	1.51e-05	0.00026	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LPL—metabolic syndrome X	1.49e-05	0.000257	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NAMPT—metabolic syndrome X	1.47e-05	0.000254	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGT—metabolic syndrome X	1.46e-05	0.000253	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—metabolic syndrome X	1.46e-05	0.000253	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LIPC—metabolic syndrome X	1.46e-05	0.000253	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GCK—metabolic syndrome X	1.46e-05	0.000253	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOS3—metabolic syndrome X	1.46e-05	0.000252	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOC3—metabolic syndrome X	1.45e-05	0.000251	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOE—metabolic syndrome X	1.43e-05	0.000248	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LEP—metabolic syndrome X	1.43e-05	0.000248	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOA1—metabolic syndrome X	1.42e-05	0.000245	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CETP—metabolic syndrome X	1.41e-05	0.000244	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SCARB1—metabolic syndrome X	1.35e-05	0.000234	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC2A4—metabolic syndrome X	1.34e-05	0.000232	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCA1—metabolic syndrome X	1.34e-05	0.000232	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	1.32e-05	0.000227	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SREBF1—metabolic syndrome X	1.31e-05	0.000227	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GGT1—metabolic syndrome X	1.3e-05	0.000225	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GOT1—metabolic syndrome X	1.3e-05	0.000225	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IRS1—metabolic syndrome X	1.28e-05	0.000221	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMGCR—metabolic syndrome X	1.28e-05	0.000221	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GOT2—metabolic syndrome X	1.28e-05	0.000221	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGT—metabolic syndrome X	1.27e-05	0.00022	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—metabolic syndrome X	1.25e-05	0.000216	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LEP—metabolic syndrome X	1.25e-05	0.000215	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOE—metabolic syndrome X	1.25e-05	0.000215	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOA1—metabolic syndrome X	1.23e-05	0.000213	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—metabolic syndrome X	1.23e-05	0.000213	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—INS—metabolic syndrome X	1.23e-05	0.000212	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL2—metabolic syndrome X	1.21e-05	0.000208	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1—metabolic syndrome X	1.18e-05	0.000205	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	1.15e-05	0.000199	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCA1—metabolic syndrome X	1.14e-05	0.000197	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC2A4—metabolic syndrome X	1.14e-05	0.000197	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—metabolic syndrome X	1.14e-05	0.000196	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SERPINE1—metabolic syndrome X	1.13e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IRS1—metabolic syndrome X	1.11e-05	0.000192	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOB—metabolic syndrome X	1.1e-05	0.000191	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GGT1—metabolic syndrome X	1.1e-05	0.00019	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GOT1—metabolic syndrome X	1.1e-05	0.00019	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOS3—metabolic syndrome X	1.07e-05	0.000186	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PLA2G4A—metabolic syndrome X	1.07e-05	0.000185	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—INS—metabolic syndrome X	1.06e-05	0.000184	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LPL—metabolic syndrome X	1.05e-05	0.000182	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL2—metabolic syndrome X	1.05e-05	0.000181	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1—metabolic syndrome X	1.03e-05	0.000178	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CD36—metabolic syndrome X	1e-05	0.000173	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SERPINE1—metabolic syndrome X	9.77e-06	0.000169	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—metabolic syndrome X	9.65e-06	0.000167	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOB—metabolic syndrome X	9.34e-06	0.000162	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOS3—metabolic syndrome X	9.33e-06	0.000161	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARA—metabolic syndrome X	9.3e-06	0.000161	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—metabolic syndrome X	9.21e-06	0.000159	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLA2G4A—metabolic syndrome X	9.09e-06	0.000157	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—metabolic syndrome X	9.06e-06	0.000157	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AGT—metabolic syndrome X	9.01e-06	0.000156	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LPL—metabolic syndrome X	8.92e-06	0.000154	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOE—metabolic syndrome X	8.83e-06	0.000153	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOA1—metabolic syndrome X	8.73e-06	0.000151	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CD36—metabolic syndrome X	8.48e-06	0.000147	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—metabolic syndrome X	8.36e-06	0.000145	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—metabolic syndrome X	7.99e-06	0.000138	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARA—metabolic syndrome X	7.88e-06	0.000136	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—metabolic syndrome X	7.87e-06	0.000136	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—metabolic syndrome X	7.69e-06	0.000133	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AGT—metabolic syndrome X	7.63e-06	0.000132	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—INS—metabolic syndrome X	7.54e-06	0.00013	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOE—metabolic syndrome X	7.48e-06	0.000129	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOA1—metabolic syndrome X	7.39e-06	0.000128	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—metabolic syndrome X	7.27e-06	0.000126	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—metabolic syndrome X	7.26e-06	0.000125	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—metabolic syndrome X	7.1e-06	0.000123	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—metabolic syndrome X	6.91e-06	0.00012	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—metabolic syndrome X	6.71e-06	0.000116	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NOS3—metabolic syndrome X	6.61e-06	0.000114	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—metabolic syndrome X	6.51e-06	0.000113	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—INS—metabolic syndrome X	6.39e-06	0.00011	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—metabolic syndrome X	6.17e-06	0.000107	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—metabolic syndrome X	6.05e-06	0.000105	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—metabolic syndrome X	5.86e-06	0.000101	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NOS3—metabolic syndrome X	5.6e-06	9.69e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—metabolic syndrome X	5.35e-06	9.25e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—metabolic syndrome X	5.12e-06	8.86e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—metabolic syndrome X	4.94e-06	8.54e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—metabolic syndrome X	4.65e-06	8.04e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—metabolic syndrome X	4.29e-06	7.41e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—metabolic syndrome X	3.04e-06	5.26e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—metabolic syndrome X	2.58e-06	4.45e-05	CbGpPWpGaD
